Rheumatoid Arthritis: A Year in Progress


individuals cope with this disease. In addition to better understand how to use existing drugs, in 2015 a new class of drugs called JAK 1/2 inhibitors emerged and appears promising. Also, the anti-IL17 antibody, secukinamab, appears to benefit patients with ankylosing spondylitis (AK) as well as psoriatric arthritis (PsA).

For prevention of joint erosion, a new drug combination shows promise for patients at risk of joint destruction, and the combination of Cimzia plus methotrexate significantly slows inflammation in the joints for patients with early RA who are at risk of poor prognosis. Studies continue to support treat to target and measures of disease activity like Vectra continue to be refined to guide physicians and patients toward optimal therapy. Looking ahead, researchers will be putting forth continued effort to understand the bodys immune system to create more targeted drugs for further management of this chronic and debilitating auto-immune disease.

RA News

Psoriatric Arthritis

Ankylosing Spondylitis

Ask the Expert Web Chats


Knowledge is Power

Are you facing a new diagnosis of RA, suffering an RA flare, living with an auto-immune disease, or supporting a loved one through their RA journey?

  • Sign up for monthly newsletters on RA here.
  • Get support information for RA here.
  • Join theRAConnection online support group to join ongoing discussions with other individuals affected by RA here.
  • Follow theRAConnection on Facebook and Twitter.

Rheumatoid Arthritis